STOK Latest Press Releases

-- October 22, 2026 --

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates Business Wire 8:00 AM

-- October 16, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:20 PM

-- October 12, 2026 --

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting Business Wire 8:00 AM

-- October 6, 2026 --

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting Business Wire 8:00 AM

-- October 5, 2026 --

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Business Wire 7:00 AM

-- September 23, 2026 --

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization Business Wire 4:01 PM

-- September 16, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- September 3, 2026 --

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Globe Newswire 7:30 PM

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Business Wire 7:30 PM

-- September 2, 2026 --

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference Business Wire 8:00 AM

-- September 1, 2026 --

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Business Wire 7:30 AM

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) Globe Newswire 7:30 AM

-- August 18, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- August 5, 2026 --

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference Business Wire 8:00 AM

-- August 3, 2026 --

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates Business Wire 4:01 PM

-- July 27, 2026 --

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates Business Wire 4:01 PM

-- July 16, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- July 13, 2026 --

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer Business Wire 7:30 AM

-- June 30, 2026 --

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome Business Wire 8:00 AM

-- June 16, 2026 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- May 28, 2026 --

Stoke Therapeutics to Present at Upcoming Investor Conferences in June Business Wire 4:01 PM

Market Data Delayed 15 Minutes